Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
OncoGenex Pharmaceuticals |
---|---|
Information provided by: | OncoGenex Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00034177 |
Phase IIA, multicenter, dose escalation study evaluating the safety and efficacy of weekly S-8184 paclitaxel injectable emulsion in second line treatment of patients locally advanced, metastatic, or recurrent transitional cell carcinoma of the urothelium.
Condition | Intervention | Phase |
---|---|---|
Urologic Neoplasms |
Drug: S-8184 Paclitaxel Injectable Emulsion Drug: Experimental Arm: TOCOSOL Paclitaxel |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Safety And Efficacy Of Weekly Administration Of S-8184 Paclitaxel Injectable Emulsion In Second Line Treatment Of Patients With Locally Advanced, Metastatic, Or Recurrent Transitional Cell Carcinoma Of The Urothelium |
Enrollment: | 27 |
Study Start Date: | April 2002 |
Study Completion Date: | September 2007 |
Primary Completion Date: | September 2007 (Final data collection date for primary outcome measure) |
The goals of this study are to determine the objective response rate, to determine time to disease progression, duration of response, and survival, and to identify the maximum tolerated weekly dose and principal toxicities of S-8184 in this patient population.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | OncoGenex Pharmaceuticals ( Monica Krieger, VP Regulatory Affairs ) |
Study ID Numbers: | SON-8184-1065 |
Study First Received: | April 23, 2002 |
Last Updated: | June 2, 2009 |
ClinicalTrials.gov Identifier: | NCT00034177 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Locally Advanced, Metastatic, or Recurrent Transitional Cell Carcinoma of the Urothelium |
Urinary Tract Neoplasm Paclitaxel Tubulin Modulators Urogenital Neoplasms Antimitotic Agents Urologic Neoplasms |
Carcinoma, Transitional Cell Antineoplastic Agents, Phytogenic Recurrence Transitional Cell Carcinoma Neoplasms, Glandular and Epithelial Carcinoma |
Neoplasms by Histologic Type Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Mitosis Modulators Urogenital Neoplasms Antimitotic Agents Carcinoma, Transitional Cell Urologic Neoplasms Pharmacologic Actions |
Carcinoma Neoplasms Neoplasms by Site Paclitaxel Therapeutic Uses Tubulin Modulators Antineoplastic Agents, Phytogenic Neoplasms, Glandular and Epithelial |